A meta-analysis of 413 ovarian cancer patients and 573 controls concluded that urine HE4 has potential as a diagnostic biomarker in ovarian cancer, but was limited by marked heterogeneity of included studies with respect to diagnostic thresholds, in addition to small sample sizes [38]. This evidence concerns the gene WFDC2 and ovarian carcinoma.